SHILPAMED Shilpa Medicare Ltd Contract Awards Announcement 2024 - Fast-Track Designation Shilpa Medicare Limiteds customer has received Fast Track Designation from the USFDA for an investigational drug candidate aimed at treating Glioblastoma, with clinical trials planned to begin soon. Shilpa is providing end-to-end development services for this drug, which is notable as no new drug for Glioblastoma has been approved in over two decades..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd